Enlivex Therapeutics
- Country
- ๐ฎ๐ฑIsrael
- Ownership
- Public
- Established
- 2005-10-01
- Employees
- 49
- Market Cap
- -
- Website
- http://www.enlivex.com
- Introduction
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)โข Click on a phase to view related trials
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06522035
- Locations
- ๐ฎ๐ฑ
Meir Medical Center, Kfar Saba, Israel
๐ฎ๐ฑRambam Medical Center, Haifa, Israel
๐ฎ๐ฑCarmel Medical Center, Haifa, Israel
Study of Intra-articular Allocetra in Knee Osteoarthritis
- Conditions
- Osteoarthritis, Knee
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06233474
- Locations
- ๐ฒ๐ฉ
IMSP Institutul de Cardiologie, Chisinau, Moldova, Republic of
๐ฒ๐ฉSpitalul Clininc Republican "T. Mosneaga", Chisinau, Moldova, Republic of
๐ฒ๐ฉIMSP Sptalul Clinic Municipal "Sfanta Treime", Chisinau, Moldova, Republic of
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04922957
- Locations
- ๐ฎ๐ฑ
Hadassah Ein Kerem Medical Center, Jerusalem, Israel
Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04659304
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Community-acquired PneumoniaSepsisCholecystitis, AcuteUrinary Tract InfectionsCholangitis AcuteIntraabdominal Infections
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04612413
- Locations
- ๐ง๐ช
Clinique Saint-Pierre, Brussel, Belgium
๐ง๐ชSaint-Luc Hospital University, Brussel, Belgium
๐ง๐ชCHU de Charleroi, Charleroi, Belgium
- Prev
- 1
- 2
- Next